Published in FDA Law Weekly, May 7th, 2009
Cost of Sales and Operating Expenses. -- Earnings Rise 24% (reported) or 36% (pro forma non-GAAP) to $1.20 per
share. Eli Lilly and Company (NYSE:LLY) announced financial results for the first quarter of 2009. Due to significant strategic actions taken by the company in 2008, financial results for 2008 are presented on both a reported basis and a pro forma non-GAAP basis. Reported results were prepared in accordance with generally accepted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.